Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study-Reference-Cited by-同舟云学术

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:400-402
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wong Sandy W.¹,Bar Noffar²,Paris Laura³,Hofmeister Craig C⁴,Hansson Markus⁵,Santoro Armando⁶⁷,Mateos Maria-Victoria⁸,Rodríguez-Otero Paula⁹,Lund Johan¹⁰,Encinas Cristina¹¹,Yee Andrew J.¹²,Oriol Albert¹³,Cerchione Claudio¹⁴,de la Rubia Javier¹⁵,Ferstl Barbara¹⁶,Carlson Kristina¹⁷,Ribas Paz¹⁸,Bermúdez Arancha¹⁹,Boss Isaac W.²⁰,Gaudy Allison²¹,Li Shaoyi²²,Hsu Kevin²³,Godwin Colin D.²⁴,Burgess Michael R.²⁵,San-Miguel Jesús²⁶,Costa Luciano J.²⁷

Affiliation:

1. 1Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA

2. 2Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT

3. 3Hematology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

4. 4Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

5. 5Skåne University Hospital, Lund, Sweden

6. 6Department of Biomedical Sciences, Humanitas University, Milan, Italy

7. 7IRCCS Humanitas Research Hospital - Humanitas Cancer Center Rozzano, Milan, Italy

8. 8Department of Hematology, and Center for Cancer Research, University Hospital of Salamanca, Salamanca, Spain

9. 9Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain

10. 10Haematology Center, Karolinska University Hospital, Stockholm, Sweden

11. 11Hematology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain

12. 12Massachusetts General Hospital Cancer Center, Boston, MA

13. 13Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain

14. 14Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy

15. 15Hematology Department, University Hospital La Fe, Valencia, Spain

16. 16Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

17. 17Department of Hematology, Uppsala University Hospital, Uppsala, Sweden

18. 18Department of Hematology, Hospital Universitario Dr Peset Aleixandre, Valencia, Spain

19. 19Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain

20. 20Translational Research, Bristol Myers Squibb, Seattle, WA

21. 21Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Summit, NJ

22. 22Biostatistics, Bristol Myers Squibb, Berkley Heights, NJ

23. 23Early Clinical Development, Bristol Myers Squibb, Summit, NJ

24. 24Early Clinical Development, Bristol Myers Squibb, Seattle, WA

25. 25Early Clinical Development, Bristol Myers Squibb, Princeton, NJ

26. 26Applied Medical Research, Clínica Universidad de Navarra, Pamplona, Spain

27. 27University of Alabama at Birmingham Hospital, Vestavia, AL

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11

2. Current landscape of CD3 bispecific antibodies in hematologic malignancies;Trends in Cancer;2024-08

3. Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies;Expert Opinion on Biological Therapy;2024-07-29

4. Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study;HemaSphere;2024-07

5. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma;Cancers;2024-06-26